Published in
Taylor and Francis Group, Expert Opinion on Biological Therapy, 12(22), p. 1579-1584, 2022
DOI: 10.1080/14712598.2022.2070428
Links
Tools
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis
Journal article published in 2022 by
Paolo Gisondi 
,
Davide Geat,
Patrizio Armeni,
Francesco Bellinato ,
Martina Maurelli ,
Giampiero Girolomoni
,
Davide Geat,
Patrizio Armeni,
Francesco Bellinato ,
Martina Maurelli ,
Giampiero Girolomoni
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 